Health Industry Updates: Psychedelic Drug Stocks Rise Amid FDA Acceleration Order
Shares of psychedelic drug companies surged following an executive order by President Trump directing expedited FDA reviews of such treatments. AtaiBeckley, Compass Pathways, Enveric BioSciences, GH Research, and other firms saw significant stock gains. The order also called for increased federal funding for psychedelic research.
Psychedelic drug companies enjoyed a stock market boost after President Donald Trump signed an order mandating the U.S. Food and Drug Administration (FDA) expedite reviews of psychedelic treatments. This move sparked gains for key industry players like AtaiBeckley and Compass Pathways.
The executive order also increases federal research funding for burgeoning psychedelic therapies. Enveric BioSciences, GH Research, and Definium Therapeutics saw their shares climb, amid hopes for accelerated market entry and expanded consumer access.
Trump's initiative underscores a growing government interest in harnessing psychedelics for medical purposes, propelling stock prices of several U.S.-listed psychedelic firms upwards in response to the news.
ALSO READ
-
Psychedelic Rally: Stocks Surge as FDA Ramps Up Reviews
-
Psychedelic Drug Developers Surge as Trump Expedites FDA Reviews
-
Transparency Calls in FDA Drug Approvals Stir Tensions
-
US FDA Approves Waters' At-Home Cervical Cancer Screening Kit
-
US FDA Approves At-Home Cervical Cancer Kit Amid Global Health Shakeups
Google News